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SUMMARY
Ménière’s disease (MD) is a chronic condition characterised by fluctuating hearing loss, intermittent vertigo, tinnitus and aural fullness. 
Its anatomical and pathological counterpart is represented by endolymphatic hydrops (EH). Recent development and progress in magnetic 
resonance (MR) imaging techniques has enabled visualisation of EH in living human subjects using a 3 Tesla (T) scanner and gadolinium-
based contrast-agent (GBCA) via intravenous (IV) or intra-tympanic (IT) administration. Data emerging from the literature about MR im-
aging of EH in MD patients are limited, and we therefore reviewed the most common MR imaging findings in the study of the endolym-
phatic space in both MD and non-MD patients.
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RIASSUNTO 
La malattia di Ménière è una condizione cronica caratterizzata da sordità, vertigini, acufeni e sensazione di aumento della pressione intra 
auricolare. La sua controparte anatomo-patologica è l’idrope endolinfatica. I recenti progressi in campo di imaging di risonanza magneti-
ca (RM) hanno permesso di visualizzare la presenza di idrope endolinfatica in vivo mediante l’acquisizione di immagini su scanner 3 Tesla 
dopo la somministrazione di mezzo di contrasto per via endovenosa o intratimpanica. I recenti dati di letteratura sull’imaging RM della 
sindrome di Ménière e la caratterizzazione dell’idrope endolinfatica sono tuttavia contradditori. Obiettivo di questo lavoro è la revisione 
dei reperti radiologici RM più comuni nello studio dell’idrope endolinfatica in pazienti affetti e non affetti da sindrome di Ménière.
PAROLE CHIAVE: Imaging di Risonanza Magnetica • Idrope endolinfatica • Malattia di Ménière • Coclea • Vestibolo
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Introduction
Ménière’s disease (MD) is a chronic condition charac-
terised by fluctuating hearing loss, intermittent vertigo, 
tinnitus and aural fullness. It is a relatively common dis-
order, with a prevalence of 200-500 per 100,000  1. Its 
anatomical and pathological counterpart is represented 
by endolymphatic hydrops (EH), a distension of the en-
dolymphatic space of the inner ear into areas that are 
normally occupied by the perilymphatic space. The most 
common affected areas are the cochlear duct and the sac-
cule, but EH may also involve the utriculum and semicir-
cular canals 2. Guidelines for diagnosis of this syndrome 
were established in 1995 by the American Academy of 
Otolaryngology  - Head and Neck Surgery (AAO-HNS). 
The most recent and revised classification considers two 
major categories: definite and probable Ménière’s dis-
ease 3. Diagnosis of definite MD is made by the presence 
of two or more episodes of vertigo, audiometrically docu-
mented low-to-medium frequency sensorineural hearing 
loss in one hear, and fluctuating aural fullness. Probable 
MD is defined by two or more episodes of vertigo, and 
fluctuating aural fullness in the affected ear  4. To evalu-
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ate the presence of EH, both electronystagmography and 
electrocochleography tests can be used, which reflect the 
reduced vestibular response and the elevation of inner ear 
pressure through distension of the basilar membrane, re-
spectively. An emerging technique in assessment of EH 
is vestibular evoked myogenic potential (VEMP), a neu-
roelectrophysiological test that evaluates the otolithic or-
gans of the utricle and saccule. VEMP may be abolished 
in patients with EH in the vestibule. Imaging studies in the 
past were mainly used to exclude retro cochlear disorder, 
such as schwannoma. However, the recent development 
and progress of magnetic resonance (MR) imaging tech-
niques has enabled visualizsation of EH in living human 
subjects using a 3 Tesla (T) scanner and gadolinium-based 
contrast-agent (GBCA) via intravenous (IV) or intra-
tympanic (IT) administration 5 6. Data from the literature 
about MR imaging of EH in MD patients are limited due 
to discrepancies in patient selection and MR assessment 
criteria. For this reason, our purpose is to provide insight 
of the current MD imaging scenario. We reviewed the 
main techniques in assessment of EH and most common 
MR imaging findings in study of the endolymphatic space 
in both MD and non-MD patients.
MR findings in MD patients 
In June 2017, a structured search was performed in Pub-
Med using the following key words: “MRI” AND “endo-
lymphatic hydrops” (n = 153), “MRI” AND “Ménière’s 
disease” (n = 213). The search was filtered for studies on 
human subjects and published in English language. In 
order to have a clearer view of the potential diagnostic 
role of MR imaging in the assessment of patients with 
MD, we analysed only MR findings of studies on patients 
with definite MD according to the AAO-HNS criteria, 
who underwent MR imaging at 3 Tesla scanner with IT or 
IV administration of GBCA and volumetric acquisition. 
We excluded from the review: 1) case reports, reviews and 
metanalysis; 2) studies on patients enrolled according to 
diagnostic criteria other than those of the AAO-HNS, or 
in which clinical evidence of diagnosis (“definite”, “prob-
able” or “possible”) according to those criteria was not 
specified; 3)  studies in which the hydrops was not as-
sessed by MR standardised qualitative, quantitative or 
semi-quantitative methods; 4) studies in which a per-ear 
analysis (symptomatic ear versus asymptomatic ear) of 
MR findings was not performed for each subject. 
After the titles and abstracts of preliminary articles were 
read, 18 articles were deemed eligible. Two readers (F.L. 
and S.C., radiology residents with 1-3 years of experi-
ence in otoradiology, respectively) then read the articles 
in their entirety, confirming the eligibility for 17 of them. 
They subsequently extracted the following information 
from eligible studies: first author, total number of subjects 
(MD patients and controls), MR acquisition and analy-
sis methods and MR findings of particular interest for the 
evaluation of the hydrops in the symptomatic/asympto-
matic ears of the enrolled subjects. 
Results are reported separately for studies adopting IT-
GBCA administration and those adopting IV-GBCA ad-
ministration. The results of the search are summarised in 
Tables I and II.
Results and discussion
MR technique
MR assessment of the endolymphatic space can be per-
formed using both IT and IV administration of GBCA 7. 
The IT-GBCA technique consists in IT administration of 
0.3-0.6 ml of GBCA, diluted 8-fold, into the tympanic 
cavity by puncture of the tympanic membrane. The con-
trast medium diffuses into the perilymph, but not in the 
endolymph, depending on the permeability of the round 
window, giving a perilymph positive image (PPI) 8. MR 
imaging is usually performed at 24 hours after administra-
tion, and a heavily T2-weighted 3D-FLAIR sequence with 
variable flip angle is usually preferred. The endolabyrinth 
appears to have a lower signal compared to the surround-
ing perilymph. The inversion time of the 3D-FLAIR can 
also be shortened to suppress the signal of the perilymph 
and increase that of the endolymph, thus giving a posi-
tive endolymphatic image (PEI) 9. 3D inversion-recovery 
turbo spin-echo with real reconstruction (3D-real IR) al-
lows to separate the signals from the perilymph (positive), 
endolymph (negative) and surrounding bone (zero) using 
an inversion time between the null point of the perilymph 
containing the contrast medium and the endolymph. How-
ever, this sequence is less sensitive to low GBCA concen-
trations than 3D-FLAIR 9.
The IV-GBCA technique consists in IV administration of 
a recommended dose of GBCA (usually 0.1 or 0.2 ml/Kg) 
that slowly accumulates in the perilymph, but not in the en-
dolymph, depending on the permeability of the blood-laby-
rinthine barrier, thus giving a PPI 10. Two types of sequences 
are recommended: 3D-real IR or heavily T2-weighted 3D-
FLAIR 7. The optimal time for MR acquisition is about 4 
hours from the contrast-medium administration as demon-
strated in another study concerning various fluid-containing 
spaces 10. It is important to note that the visibility of the en-
dolymphatic space depends on the inversion time. For this 
reason, it is recommended to acquire MR images in control 
subjects, in order to establish the normal standard for these 
sequences. MR images can be directly evaluated after acqui-
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sition or read post-processed. For example, in HYDROPS 
images (Hybrid of the reversed image of the positive endo-
lymph signal and native image of positive perilymph signal) 
the PEI is subtracted from the PPI  10. HYDROPS2 is re-
constructed by subtracting the MR cisternography sequence 
(usually 3D heavily T2-weighted Turbo spin echo sequence 
with variable flip-angle) from the PEI  11. HYDROPS and 
HYDROPS2 can be multiplied for the MR cisternography 
image to further increase the contrast-to-noise ratio (CNR) 
obtaining the HYDROPS-Mi2 and HYDROPS2-Mi2 im-
ages, respectively 12. Some authors suggest that the use of 
maximum intensity projection (MIP) reconstruction of 
heavily T2-weighted 3D-FLAIR represents a robust and ac-
curate method for assessment of EH 13.
Although IT-GBCA technique has a big advantage of 
creating a stronger perilymph signal, the IV-GBCA tech-
nique is preferred as it is less invasive, requires only four 
hours to complete the MR examination and allows study 
of both ears in the same session 7.
Findings for IV-GBCA administration
The most common method for assessment of the vestibular 
and cochlear endolymphatic spaces was firstly described 
by Nakashima et al. 14 (Figs. 1-3). This method assesses 
the vestibular endolymphatic space (VES) by calculat-
ing the ratio of the area of the VES to the entire vestibule 
(VES/vestibule ratio) in the axial plane and defining the 
vestibular EH (vEH) absent if this ratio is < 33%, mild if 
between 33% and 50% and significant if > 50%. In ad-
dition, Nakashima et al.  14 evaluated the cochlear endo-
lymphatic space looking at displacement of Reissner’s 
membrane and defining the cochlear EH (cEH) as mild 
if there is a Reissner’s membrane displacement with the 
area of the endolymphatic compartment not exceeding the 
area of the scala vestibule, and as significant when the 
endolymphatic compartment exceeds the area of the scala 
vestibule 8. While the aforementioned diagnostic criteria 
for cEH are used by almost all authors, different cut-offs 
of the VES/vestibule ratio for the identification vEH were 
further proposed. 
Mild vEH, according to Nakashima’s criteria, was report-
ed from 94% to 100% of symptomatic ears of MD patients, 
but also from 53% to 100% of asymptomatic ears  15-17. 
Sano et al. detected mild vEH in 4/6 (66%) symptomatic 
ears of patients with other otological diseases 15. Attyè et 
al. identified at least mild vEH in 27/30 (90%) ears of 
healthy volunteers 18. These data suggest that a VES/ves-
tibule ratio > 33% has a low specificity in identifying the 
Table I. MR findings for IV-GBCA technique. 
Articles MR sequence  
(TR/TI/TE)
Reference MR criteria 
for the assessment  
of EH
Percentage (%)  
of EH  
in symptomatic  
MD ear
Percentage (%)  
of EH  
in asymptomatic  
MD ear
Percentage (%) 
of EH in ears with 
other audiological 
disorders
Percentage (%)  
of EH  
in healthy ears
Pakdamn 
et al 19
3D-FLAIR 
(9000/2350/534)
vEH if VES/vestibule > 50%
vEH: 22/32 (68%) vEH: 0/32 (0%) vEH: 0/11 (0%) vEH: 0/11 (0%)
cEH: not investigated
Sano  
et al. 15
3D-FLAIR 
(9000/2400/540)
vEH if VES/vestibule > 33% vEH 1/1 (100%) vEH: 1/1 (100%) vEH: 4/6 (66%) vEH: 2/4 (50%)
cEH if cochlear duct is dilatated cEH: 1/1 (100%) cEH: 1/1 (100%) cEH: 4/6 (66%) cEH: 0/4 (0%)
Barath  
et al. 21
3D-real IR 
(6000/2000/177)
vEH if VES/vestibule > 50%
EH: 41/43 (95%) EH: 10/45 (22%) NA NA
cEH if cochlear duct is dilatated
Sepahdari 
et al. 13
3D-FLAIR 
(9000/2350/534)
vEH if VES/vestibule > 45%
vEH: 6/12 (50%) NA NA NA
cEH: not reported
Yoshida  
et al. 16
3D-FLAIR
 (not specified)
vEH if VES/vestibule > 33% vEH: 49/52 (94%) vEH; 17/32 (53%)
NA
vEH: 3/42 (7%)
cEH if cochlear duct is dilatated cEH: 45/52 (86%) cEH: 15/32 (46%) cEH: 16/42 (33%)
Tagaya  
et al. 17
3D-FLAIR
(not specified)
vEH if VES/vestibule > 33% vEH: 7/7 (100%) vEH: 3/5 (60%)
NA
cEH if cochlear duct is dilatated cEH: 5/7 (71%) cEH: 1/5 (20%)
Attyè  
et al. 18
3D-FLAIR 
(7600/2300/345)
vEH if VES/vestibule > 50% vEH: 14/30 (46%)
NA NA
vEH: 9/30 (30%)
cEH if cochlear duct is dilatated cEH: 11/30 (36%) cEH: 4/30 (13%)
Sepahdari 
et al. 22
3D-FLAIR 
(9000/2350/534)
vEH if VES/vestibule > 50%
EH: 7/7 (100%) EH: 0/7 (0%) NA NA
cEH if cochlear duct is dilatated
Attyè  
et al. 20
3D-FLAIR 
(8000/2400/316)
vEH if VES/vestibule > 50%
EH: 73/95 (77%) EH: 9/41 (21%)
vEH: 15/128 (11%)
NA
cEH if cochlear duct is dilatated cEH: 31/128 (24%)
EH = endolymphatic hydrops; cEH = cochlear endolymphatic hydrops; vEH = vestibular endolymphatic hydrops; NA = not available; TE = echo time; TI = inversion time;  
TR = time of repetition.
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affected ear of MD patients with unilateral symptoms and 
in differentiating MD from other otological diseases in 
which a secondary vEH can occur. However, this cut-off 
could represent a rule out factor in MD patients in which 
a define diagnosis has not been clinically reached, due to 
its high sensitivity. 
Severe vEH, according to Nakashima’s criteria, was found 
in 46% and 68% of the symptomatic MD ears in two stud-
Table II. MR findings for IT-GBCA technique.
Articles MR sequence  
(TR/TI/TE)
Reference MR criteria 
for the assessment  
of EH
Percentage (%)  
of EH  
in symptomatic  
MD ear
Percentage (%)  
of EH  
in asymptomatic  
MD ear
Percentage (%)  
of EH in ears with  
other audiological  
disorders
Percentage (%)  
of EH  
in healthy ears
Hornibrook  
et al. 29
3D-FLAIR  
(TI 2500)
vEH if VES/vestibule > 33%
EH: 14/30 (47%) NA EH: 3/45 (7%) NA
cEH if cochlear duct is dilatated
Wu  
et al. 25
3D-FLAIR 
(6000/2100/387)
vEH if VES/vestibule > 50%
vEH: 75/108 (69%)
vEH: 1/108
NA NA
cEH: if cochlear duct is dilatated cEH: 9/108
Claes  
et al. 24
3D-FLAIR 
(9000/1700/134 )
vEH if VES/vestibule > 33% vEH 2/12 (16%)
NA NA NA
cEH if cochlear duct is dilatated cEH: 3/12 (25%)
Bykowski  
et al. 30
2D-FLAIR 
(9454/2500/122)
vEH if VES/vestibule > 33% vEH 6/6 (100%
NA NA NA
cEH if cochlear duct is dilatated cEH: 6/6 (100%)
Naganawa  
et al. 27
3D-FLAIR 
(9000/2250/544)
vEH if VES/vestibule > 33% vEH: 8/9 (89%) vEH: 5/9 (55%)
NA NA
cEH: note reported cEH: 6/9 (67%) cEH: 4/9 (44%)
Lida  
et al. 26
3D-FLAIR 
(9000/2500/130)
vEH if VES/vestibule > 33% vEH: 9/11 (81%) vEH; 6/9 (67%)
NA NA
cEH if cochlear duct is dilatated cEH:9/11 (81%) cEH: 6/9 (67%)
Shi  
et al. 23
3D-FLAIR 
(9000/2500/128)
vEH if VES/vestibule > 33%
EH: ¾ (75%) NA NA NA
cEH if cochlear duct is dilatated
Suga  
et al. 28
3D-FLAIR 
(NA)
vEH if VES/vestibule > 33% vEH 4/6 (67%) vEH 1/1 (100%)
cEH if cochlear duct is dilatated cEH 4/6 (67%) cEH 1/1 (100%)
EH = endolymphatic hydrops; cEH = cochlear endolymphatic hydrops; vEH = vestibular endolymphatic hydrops; NA = not available; TE = echo time; TI = inversion time;  
TR = time of repetition.
Fig. 1. a) and b) T2-weighted FLAIR and schematic illustration image depicting the normal appearance of the vestibular endolymphatic space: the saccule 
(straight arrow) and the utricule (curved arrow) occupy less than 33% of the vestibular space (VES/vestibule ratio); there is no enlargement of endolymphatic 
space in the cochlea.
a) b)
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ies  18  19. However, Pakdaman et al. did not find it in 32 
asymptomatic ears of MD patients  19. Furthermore, vEH 
was reported in a range from 0% to 30% of asymptomatic 
ears of healthy volunteers 18 19. Severe vEH was identified in 
15/128 (11%) and 0/11 (0%) symptomatic ears of patients 
with other otological diseases, respectively 19 20. 
Although the VES/vestibule ratio > 50% may have a low-
er sensitivity to detect MD ears, these data suggest that it 
may represent a rule in criteria for MD, since it has a good 
specificity in both differentiating MD ears from healthy 
ears and those affected by other otological disorders. 
Other potential cut-off values were investigated. Sepah-
dari et al. calculated a VES/vestibule ratio of 45% as two 
standard deviations above the mean of a group of patients 
Fig. 2. a) and b) T2-weighted FLAIR and schematic illustration of the endolymphatic space image demonstrate the presence of mild vEH, with a VES/vestibule 
ratio > 33% (straight arrow points to saccule; curved arrow points to utricle); there is also mild cEH, represented by displacement of the Reissner’s membrane 
with the area of the endolymphatic compartment not exceeding the area of the scala vestibule (arrow-head).
Fig. 3. a) and b) T2-weighted FLAIR and schematic illustrations of the endolymphatic space image show both significant vEH and cEH. VES/vestibule 
ratio is > 50% (straight arrow points to saccule; curved arrow points to utricle) and the endolymphatic compartment exceeds the area of the scala ves-
tibuli (arrow-head).
a)
a)
b)
b)
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with sensorineural hearing loss 13. Using this cut-off val-
ue, they found vEH in 6/12 of the symptomatic ears of 
MD patients (50%) suggesting that this diagnostic crite-
rion cannot be used to exclude a form of MD presenting 
with sudden hearing loss 13. Yoshida et al. reported that a 
VES/vestibule cut-off value of 41.9%, calculated by the 
ROC curve, has a sensitivity of 88.5% and a specificity of 
100% in differentiating MD from healthy ears 16. 
According to Nakashima’s criteria, cEH was found in 36%-
86% of symptomatic ears in three large cohorts of MD pa-
tients 16-18. Yoshida et al. also assessed asymptomatic ears 
of both MD patients and healthy volunteers, detecting cEH 
in 46% and 33% of them, respectively 16. Attyè et al. found 
cEH in 13% of healthy volunteers  18. The latter research 
group found cEH in 24% of ears of patients with recur-
rent peripheral vestibulopathy  20. These data suggest that 
cEH, as defined by Nakashima’s criteria, cannot be used 
to rule out MD, and can be found in approximately up to 
one-third of patients with other otological disease of other-
wise healthy subjects, resulting less specific and preventing 
radiologists from diagnosing MD without the support of 
clinical data. 
EH according to Nakashima’s, either vEH (VES/vestibule 
ratio > 33%) or cEH, was reported in all 60 ears (30 MD 
patients and 30 healthy subjects) studied by Attyè et al., 
giving a sensitivity of 100% but a specificity of 0% 18. In 
contrast EH, defined by the presence of either vEH (VES/
vestibule ratio > 50%) or cEH, was reported in 77%-100% 
of symptomatic ears of MD patients 18,24,25, in 0%-22% 
of asymptomatic ears (14,20-22), and in 24% of ears of 
patients with recurrent peripheral vestibulopathy 20. This 
means that the presence of EH, independently from the 
definition of vEH, could be a good criterion/parameter for 
detecting the affected side of MD patients with unilateral 
symptoms, but it does not allow radiologists to differenti-
ate MD from other otological disorders. In addition, EH 
often is not a pathologic finding, having been reported in 
a large number of healthy subjects. 
More recently, another research group assessed hydrops 
using a saccular morphology-based method. The authors 
defined saccular hydrops as a saccule to utricle ratio 
(SURI) ≥ 1, reaching a sensitivity of 50% (15/30 patients) 
and a specificity of 100% in differentiating the sympto-
matic ears of patients with Ménière’s disease from the 
asymptomatic ears of 30 healthy volunteers 18. However, it 
still remains unclear what the diagnostic role of this meth-
od is in differentiating MD from other otologic disorders. 
Findings for IT-GBCA administration
When studying MD patients by IT-GBCA administration, 
Nakashima’s method to investigate and assess the vestibu-
lar and cochlear endolymphatic spaces should be used, as 
it represents a suitable and reliable method 14.
Based on the common knowledge of drugs entry through 
an oval window pathway in rats, Shi et al. were among the 
first able to demonstrate a compromised passage through 
the oval window, showing vEH in 3 of 4 patients with 
definite MD 23. Claes et al., in contrast, did not find any 
added value from the use of the IT method in evaluat-
ing the presence of EH after the injection of GBCA af-
ter a surgical procedure: the presence of cEH and vEH 
was demonstrated in a small percentage of patients (25% 
and 16% respectively) 24. A possible explanation for this 
low rate of positive findings can be found in the dilution 
factor of the administered GBCA. IT administration is 
still off-label and many patients are reluctant to receive 
a puncture to the tympanic membrane, so that unilateral 
IT injection is usually performed even in cases when bi-
lateral EH is suspected, underestimating the possible in-
volvement of the contralateral ear. The study from Wu et 
al. is one of the few in which MD patients underwent to 
a bilateral IT administration: presence of vEH was found 
in 75 of 108 symptomatic ears (69%) and found cEH in 9 
of 108 contralateral ears (8%) 25. The presence of EH in 
the contralateral asymptomatic ears was demonstrated by 
Lida et al. by using both IT and IV administration: 67% 
of asymptomatic ears were shown to have both vEH and 
cEH 26. A comparison between the results obtained after 
simultaneous IV-IT administration was made by Naga-
nawa et al., by using 3D-real IR images for IT-IV side and 
HYDROPS2 for IV 27. Only HYDROPS images were able 
to demonstrate EH in all ears VEH and cEH were demon-
strated in 89% and 67% of ears, respectively. A significant 
rate of vEH (55%) and cEH (44%) was also found in the 
contralateral asymptomatic ears 27.
Differences may also exist between the times of delayed 
postcontrast imaging, most likely being performed after 
24 hours, but in some cases after 4 hours 28. The impact 
of this discrepancy on the imaging evaluation of MD pa-
tients is unclear: Suga et al. were able to assess the pres-
ence of vEH in 4 of 6 patients with definite MD indepen-
dently from the time of acquisition  28. The presence of 
EH in other audiological disorders can be shown by IT 
administration: Hornibrook et al. assessed the presence of 
EH not only in patients with definite MD (14/30 ears), 
but also in patients with other audiological disorders (3/45 
ears), even if at a very low rate (6%)  29. To address po-
tential pitfalls in the acquisition or in the interpretation 
of the images, Bykowski et al. used an 8 channel surface 
coils and acquired MR images 26 hours after monolateral 
IT administration in 6 definite MD patients  30. Variable 
FLAIR inversion time images were used to determine the 
MR imaging of endolymphatic hydrops
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impact on fluid-suppression interpretation. 100% of defi-
nite MD patients (6/6) showed both vEH and cEH in the 
symptomatic ears. 
Conclusions
MR imaging of the endolabyrithine space can be easily 
performed using a 4 hour-delayed volumetric acquisi-
tion after IV administration of GBCA. Thus, IT admin-
istration of GBCA, which is more invasive, is not rec-
ommended. Recent achievements in this technique have 
allowed radiologists to detect cochlear or vestibular EH 
on MR imaging. However, neuroimaging evidence from 
the literature and pathological findings described in ca-
davers suggest that EH does not represent exclusive find-
ings of MD patients and is probably not always patho-
logical, since it has been often described in normal ears. 
For this reason, quantitative MR assessment is most 
likely not sufficient in diagnosis of MD, and morphol-
ogy-based criteria should be investigated. In line with 
this view, the more recent SURI method, described by 
Attyè et al.  18 represents a promising tool in differenti-
ating MD ears from ears affected by other pathologies, 
but further studies should investigate this method and 
confirm its accuracy. Along with this, it is mandatory to 
use only a 3 Tesla MR in the diagnostic workup of MD. 
We are still far from being able to use MR imaging as a 
new diagnostic tool for MD and its role remains mainly 
to exclude other diseases when clinical manifestations 
are not clear, and a definitive diagnosis of MD has not 
been reached.
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